Clinical ovarian cancer and other gynecologic malignancies最新文献

{"title":"2022-RA-1022-ESGO Implementation of machine learning in a care pathway for advanced epithelial ovarian cancer: a National Cancer Institute experience","authors":"A. Boscher, Nour Kherbeik, Franck Craynest, Ali Hammoudi, S. Bécourt, H. E. Hajj, C. Martínez-Gómez, F. Narducci, D. Hudry","doi":"10.1136/ijgc-2022-ESGO.617","DOIUrl":"https://doi.org/10.1136/ijgc-2022-ESGO.617","url":null,"abstract":"Introduction/BackgroundNowadays, the knowledge of quality indicators may enable physicians to adapt the patients’ care to current standards and recommendations. Thus, the implementation of machine learning in a care pathway can be observed as an asset. The objective of this work was to describe the development of a care pathway for advanced epithelial ovarian cancer (AEOC) using artificial intelligence, in a National Comprehensive Cancer Institute.MethodologyA multidisciplinary team defined the key steps of the AEOC pathway. Valuable indicators were defined based upon national and international guidelines. The software was educated to extract items of interest from the patient’s electronic medical record. Automatic alerts are controlled by the medical referents. Data are automatically updated daily.ResultsGradually, 17 AEOC keys steps and 21 indicators were selected. From January 2018 to April 2022, 403 patients were identified in the Turquoise pathway. The median delays were: from first call to first medical appointment, 6 days;from first appointment to laparoscopic diagnostic procedure, 12 days;from first appointment to start of primary chemotherapy if indicated: 33 days. Our center is a European Society of Gynaecological Oncology (ESGO) accredited center for ovarian cancer: the ESGO indicators for AEOC were easily available, and confirmed the intermediate center status with 72 to 117 cytoreductive surgeries per year. Adverse events were prospectively recorded, with a 8% rate of surgical complications after cytoreductive surgery. Twelve to 18% of patients were included in clinical trials. The SARS-CoV-2 pandemic impact was clearly identified with an increased number of neoadjuvant chemotherapy.ConclusionThe use of artificial intelligence has enabled the construction of a critical care pathway with real time feedback that’s helps to target the best quality of medical and surgical care. In the future, appointments will be streamlined to enhance the patients’ treatment course.","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"65 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73130776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-657-ESGO ENGOT-ov65/KEYNOTE-B96: phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer","authors":"N. Colombo, R. Coleman, Xiaohua Wu, F. Köse, R. Wenham, A. Sebastianelli, K. Hasegawa, Emese Zsíros, T. D. M. Rouge, M. Bidziński, I. McNeish, J. Sehouli, J. Korach, P. Debruyne, Jae-Weon Kim, A. C. de Melo, Xuan Peng, A. Bogusz, K. Yamada, B. Monk","doi":"10.1136/ijgc-2022-esgo.538","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.538","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73149893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-913-ESGO Clinical performance evaluation of a novel deep learning solution for homologous recombination deficiency detection","authors":"A. Buisson, P. Saintigny, A. Harlé, D. Vacirca, M. Barberis, P. Gilson, C. Roma, F. Bergantino, C. Grimm, L. Müllauer, P. Harter, S. Pignata, A. González-Martín, C. Schauer, K. Fujiwara, I. Vergote, N. Colombo, E. Pujade-Lauraine, I. Treilleux, I. Ray-Coquard","doi":"10.1136/ijgc-2022-esgo.591","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.591","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77639775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-770-ESGO Benign pseudomyxoma peritonei originated from both of ovaries and appendix with subcutaneous deployment in umbilical and inguinal of an 68 years old woman case report","authors":"S. Mongan, Glenn Ega Budi Tanoyo","doi":"10.1136/ijgc-2022-esgo.557","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.557","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81056800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-1028-ESGO Role of radiotherapy in platinum sensitive oligometastatic recurrent ovarian cancer: a valid alternative to delay systemic treatment","authors":"G. Bonaldo, R. Lazzari, S. Durante, G. Corrao, M. Lapresa, G. Parma, M. Achilarre, A. Aloisi, I. Betella, A. Garbi, L. D. De Vitis, G. Schivardi, G. Aletti, V. Zanagnolo, A. Maggioni, N. Colombo, F. Multinu","doi":"10.1136/ijgc-2022-esgo.618","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.618","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73559857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma","authors":"R. Coleman, A. Oza, D. Lorusso, C. Aghajanian, A. Oaknin, A. Dean, N. Colombo, J. Weberpals, A. Clamp, G. Scambia, A. Leary, Robert W Holloway, M. A. Gancedo, P. Fong, J. Goh, D. O’Malley, S. Goble, L. Maloney, J. Ledermann","doi":"10.1136/ijgc-2022-esgo.488","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.488","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84719088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-1329-ESGO Ovarian cancer hospitalization rates during the COVID-19 pandemic in the state of Sao Paulo and correlation with pandemic-related variables","authors":"Vinicius César Moterani, Nino Jose Wilson Moterani Junior, F. F. Pimentel, F. J. Candido dos Reis","doi":"10.1136/ijgc-2022-ESGO.692","DOIUrl":"https://doi.org/10.1136/ijgc-2022-ESGO.692","url":null,"abstract":"Introduction/BackgroundThe COVID-19 pandemic which began in 2020 disrupted healthcare services and changed patient behavior. Our objective was to identify changes in hospitalization rates of ovarian cancer patients from 2016 to 2020, comparing pre-pandemic and pandemic levels. We also aimed to assess, if these changes happened and whether they were correlated with pandemic-related variables.MethodologyAggregated data were obtained from the State of Sao Paulo Secretary of Health regarding ovarian cancer hospitalization, average social distancing rates, COVID-19 incidence, mortality, lethality, and both COVID-specific infirmary and ICU bed occupation rates. Hospitalizations for ovarian cancer were categorized as either clinical or surgical treatments. These data were available at the state level and for each state’s subdivisions. We performed a Joinpoint analysis in order to verify if there were changes regarding hospitalization rates during the study period. We also calculated hospitalization rate ratios and verified if they were correlated with pandemic-related variables.ResultsOverall hospitalization rates in the state fell coinciding with the start of the pandemic. At the state level, clinical hospitalization rates did not show changes in their trend during the study period, while surgical hospitalization rates started to decrease two trimesters before the pandemic began and remained decreasing. Surgical hospitalization rate ratios were inversely correlated with COVID-specific ICU bed occupation rates during the third trimester of 2020, with a Pearson Correlation coefficient of -0.50 (95% CI: -0.78 to -0.05, p = 0.03). An increasing number of exclusively public-insured persons were identified in the state, with a Pearson Correlation coefficient of 0.95 (95% CI: 0.88–0,98, p < 0.001).ConclusionSurgical hospitalization rate ratios fell during the third trimester of 2020 and were inversely correlated with ICU occupation. This demonstrates the impact of the COVID-19 pandemic on the treatment of conditions that compete for the same healthcare resources.","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87254537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-609-ESGO Factors related to grade iiia clavien-dindo complications and delayed time to chemotheratpy after cytoreductive surgery for advanced stage ovarian cancer: a prospective cohort study","authors":"M. Kengsakul, Gatske MNieuwenhuyzen-de Boer, S. Udomkarnjananun, S. J. Kerr, H. V. van Doorn, H. V. van Beekhuizen","doi":"10.1136/ijgc-2022-esgo.525","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.525","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87809140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-1394-ESGO Adult granulosa cell tumour of the ovary: an unexpected diagnosis","authors":"Fernanda Cristina Ribeiro Alves, Mariana Morais, Prescillia Marques, I. Sá, A. Moreira, O. Moutinho","doi":"10.1136/ijgc-2022-esgo.705","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.705","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"88 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91126142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-1638-ESGO Randomized phase III trial on Niraparib-TSR-042 (dostarlimab) versus physician’s choice in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)","authors":"V. Salutari, L. Musacchio, S. Pignata, E. Braicu, D. Cibula, N. Colombo, J. Frenel, S. Giolitto, Floriana Camarda, M. Perri, E. Giudice, G. Scambia, D. Lorusso","doi":"10.1136/ijgc-2022-esgo.762","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.762","url":null,"abstract":"higher FIGO stage(p<0.001), high-grade(p=0.003), serous tumours(p=0.006) and residual tumour as compared to local PC(p<0.001). Wet PC significantly correlated with diffuse localization(p <0.001) and residual tumour as compared to dry PC(p<0.001). Coarse PC was significantly associated with residual tumour as compared to fine PC(p=0.044). Diffuse peritoneal localization(p<0.001), wet PC(p<0.001), and lymph-node involvement(p<0.001) were associated with lower OS and PFS-rates. Conclusion Diffuse PC was a significant predictor of recurrence. Lower OS and PFS were associated with diffuse PC, wet PC, and additional lymph node involvement. Further pro-spective trials are warranted with the inclusion of translational research aspects to better understand the different peritoneal carcinomatosis pattern.","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90529249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}